Your session is about to expire
← Back to Search
nivolumab for Non-Small Cell Lung Cancer
Study Summary
This trial is looking at why some patients with lung cancer respond to treatment with nivolumab and ipilimumab, and why some patients do not.
- Non-Small Cell Lung Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 1844 Patients • NCT03068455Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had a serious allergic reaction in the past to any part of the study drug or to any other similar medications.You have received a maximum of two different types of treatment for advanced stage lung cancer in the past.If you had radiation treatment for your tumor in the past, we will check if there has been any new growth at that spot since the radiation ended.You have a lung disease that causes symptoms or may make it difficult to detect or manage potential side effects of the study drug in the lungs.You have late-stage non-small cell lung cancer.Your tumor can be safely and easily biopsied (a small sample taken for testing).If you had lung cancer and received chemotherapy before, but the cancer came back within 6 months after finishing treatment, it will count as one previous treatment.You have another type of cancer that is currently being treated and needs attention.You have a history of certain autoimmune diseases that may affect your participation in the study. However, if you have specific conditions like type I diabetes, hypothyroidism, resolved childhood asthma, or certain skin disorders that are not severe and don't require ongoing treatment, you can still join the study.
- Group 1: Nivolumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned nivolumab for therapeutic use?
"Despite the lack of efficacy data, our team at Power rated nivolumab's safety as a 2 due to its Phase 2 status."
What is the aggregate participation for this experiment?
"This clinical trial is no longer recruiting patients. Initially posted on January 1st 2015, the last edit to this listing was done on December 6th 2021. If you are interested in other studies that meet your criteria, there are 1360 trials actively enrolling people with advance directives and 718 for nivolumab treatments currently open for enrolment."
What prior research has been documented about the utilization of nivolumab?
"Presently, there are 718 active clinical trials assessing nivolumab's efficacy. Of those studies, 82 have progressed to Phase 3 with the main concentration of these triaal sites located in Basel, BE and 40237 other locations running related research."
Is there still availability for individuals to participate in this investigation?
"According to the information present on clinicaltrials.gov, this medical trial is not presently accepting new patients; however, it was posted in January 2015 and last updated in December 2021. There are currently 2,078 other trials recruiting participants at the moment."
Is this research initiative unique to the field?
"Ever since 2012, when the very first trial for nivolumab was conducted by Ono Pharmaceutical Co. Ltd., this medication has been heavily studied with 718 ongoing trials in 2354 cities and 49 different countries. After Phase 1 & 2 drug approval were granted, Nivolumab is now available to many patients worldwide."
In what treatments is nivolumab frequently employed?
"Nivolumab is utilized to treat malignant neoplasms and certain other afflictions, such as metastatic esophageal adenocarcinoma, squamous cell carcinoma of the skin or unresectable melanomas."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger